Archive for September 2024
Aspira Women’s Health Announces Publication of Data Demonstrating Performance of its In-Development Blood Test for the Assessment of Malignancy Risk in Patients with an Adnexal Mass
SUMMARY: The addition of miRNA and metadata to Aspira’s existing protein assay shows promising improvements in both sensitivity and specificity for early-stage ovarian cancer in women with an adnexal mass AUSTIN, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development…
Read MoreAspira Women’s Health to Present at the H.C. Wainwright 26th Annual Global Investment Conference
AUSTIN, Texas, Sept. 06, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, CEO of Aspira Women’s Health will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11,…
Read MoreAspira Women’s Health Selected as a Spoke for the Investor Catalyst Hub
SUMMARY: “Spoke” designation acknowledges Aspira’s position as an innovator in women’s health, and provides new opportunities for funding, thought leadership and networking with other healthcare industry leaders AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease…
Read More